To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic prostate-specific antigen (PSA) progression in patients with metastatic castrationresistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).
Introduction
Metastatic castration-resistant prostate cancer (mCRPC) causes~300 000 deaths annually worldwide [1] and is mostly a fatal disease, with a median overall survival (OS) of 3 years [2, 3] , which represents a major healthcare challenge.
During prostate cancer evolution, there is a gradual switch in sources of androgens, from endocrine production, usually sensitive to androgen deprivation therapy (ADT), to intratumoural production. mCRPC has been defined as a clinical state in which, despite suppressed circulating testosterone levels <50 ng/dL, the androgen receptor (AR) axis is reactivated, while a few patients present with an androgenindifferent disease. This reactivation is mainly attributable to the multiple signalling mechanisms in prostate cancer cells and their microenvironment [4] . AR inhibitors used as second-line hormonal therapies, such as abiraterone acetate (AA), are given with the aim of blocking the alternative sources of androgens, and have long been of interest as cancer therapeutics. Potent and selective inhibition of 17a-hydroxylase by AA blocks residual gonadal and non-gonadal androgen steroidogenesis [5] . It also inhibits adrenal glucocorticoid synthesis, resulting in an increase in adrenocorticotropic hormone (ACTH) levels by loss of negative feedback regulation of the ACTH. This increase in ACTH levels leads to an upsurge in mineralocorticoids, which does not require the 17a-hydroxylation inhibited by AA. The mineralocorticoid excess is responsible for the main side effects of AA such as hypokalaemia, hypertension and cardiac events. AA is therefore licensed in combination with prednisone (P) 10 mg daily to prevent mineralocorticoid excess [6] .
In docetaxel-naive patients AA plus P prolongs OS compared with placebo plus P [7, 8] . In such patients, AA was associated with a median progression-free survival (PFS) of 16 months and a median OS of 35 months. AA+P was also effective in patients previously treated with docetaxel [9, 10] . In these studies, AA+P was administered until radiological or symptomatic progression, regardless of PSA outcome.
A retrospective analysis reported that switching from AA+P to AA plus dexamethasone (D) was able to induce tumour responses in patients with mCRPC at biochemical progression [11] . A decline in PSA levels >30% was observed in 39.2% of patients, without significant changes in adverse effects.
Switching from P to D in the case of PSA progression with no clinical deterioration has therefore become an option for mCRPC treatment.
This retrospective analysis of a prospective cohort was designed to evaluate the effects of a corticosteroid switch from AA+P to AA+D at PSA progression, in a population of patients treated with AA+P as a first-line mCRPC without clinical or radiological progression. This study also aimed to determine predictive factors of corticoid switch efficacy.
Materials and Methods

Patients
In patients with mCRPC AA+P is one of the reference treatments. This treatment was prospectively given to all clinically asymptomatic patients with mCRPC, with an Eastern Cooperative Oncology Group performance status (ECOG-PS) score <3 between January 2013 and April 2016 in our centre.
Patients who progressed clinically/radiologically with AA+P stopped this treatment and received further lines of treatment. Patients with PSA progression without any radiological or clinical progression were prospectively switched from AA+P to AA+D, and represent the study population of this analysis.
PSA progression was defined according to the Prostate Cancer Working Group 2 criteria as a 25% rise above the nadir, confirmed by a second rise at least 3 weeks later [12] .
The steroid switch from AA+P 10 mg daily to AA+D 0.5 mg daily was performed for all patients at the time of PSA progression. The AA treatment was not discontinued and was administered at full dose, 1 000 mg daily.
The AA+D combination was administered until RECIST radiological and/or symptomatic progression. Clinical and biological evaluations were carried out every 3 months, or earlier in case of clinical deterioration. Imaging assessment with CT and bone scan was performed every 6 months, or earlier in case of biological/clinical progression.
The clinical data analysis cut-off was October 2016.
Statistical Analysis
The primary endpoint was PFS, defined as the interval between the date of corticosteroid switch and the date of radiological and/or clinical progression or patient's death.
The follow-up median was calculated using the reverse Kaplan-Meier method with 95% CI.
The Kaplan-Meier method was used to estimate PFS curves and these were described using medians with 95% CI.
Univariate Cox regression models were carried out to estimate the hazard ratio (HR) with 90% CI. All the clinical and sociodemographic variables have been tested in univariate analysis. Continuous variables were transformed in qualitative variables using several threshold values, especially median values.
Multivariate Cox models were constructed to explore independent factors influencing PFS. These models are based on the univariate results, while respecting the conditions of the Cox model's validity and the rule of Peduzzi; a maximum of one variable for 10 events was integrated [13] . All the significant variables at 10% were therefore integrated in the multivariate model. To prevent collinearity, when a variable was collinear with the more significant variable at 10% it was not integrated in the model.
Based on the multivariate Cox model, a prognostic score was built to define different risk groups. A univariate Cox model was realized according to the different risk groups.
All analyses were performed using SAS (version 9.3) and R (version 3.3.1) software.
Results
Patients Characteristics
Between January 2013 and April 2016, 93 patients were treated with AA+P in our institution ( Fig. 1) . At the time of analysis, 12 patients (12.90%) were still responding to AA+P, six (6.45%) were lost to follow-up, 23 (24.73%) displayed clinical or radiological progression, four (4.30%) discontinued the AA+P treatment for reasons other than biochemical progression, and 48 (51.61%) showed biochemical progression. A steroid switch from P 10 mg/day to D 0.5 mg/day was performed in these 48 consecutive patients with mCRPC. The median follow-up was 19.48 months (95% CI 16.07-32.92). S1 ).
Patients on AA+P n=93
Patients not eligible for the corticoid switch n=45 -12 non-biologically progressive -23 clinical and/or radiological progression -6 lost to follow-up -4 discontinuations of AA + P for other causes Patients biologically progressive, without clinical and/or radiological progression, eligible for the switch to AA+D n=48 Univariate Analysis
Among all variables tested, three were found to be favourable prognostic factors for PFS ( 
Multivariate Analysis
In multivariate analysis, different models were constructed taking into account variables' collinearity (Table 3) 
Prognostic Score
Based on the factors' significance, we retained PSA level at the time of switch and hormone sensitivity duration rather than PSA level at the time of switch and time to PSA progression on AA+P in the model. We then defined three risk scores: low risk, with two favourable prognostic factors (PSA level at the time of switch <50 ng/mL and hormone sensitivity duration ≥5 years: 14 patients); intermediate risk, with one adverse prognostic factor (PSA level at the time of switch ≥50 ng/mL and hormone sensitivity duration ≥5 years or PSA level at the time of switch <50 ng/mL and hormone sensitivity duration <5 years: 25 patients); and high risk, with two adverse prognostic factors (PSA level at the time of switch ≥50 ng/mL and hormone sensitivity duration <5 years: nine patients).
The results of Cox model analysis of the three risk scores are summarized in Table 4 . PFS curves of the three risk groups are shown in Fig. 2 . Despite the small number of patients enrolled in the present study, this scoring was able to separate outcomes with a very high degree of significance (log-rank P < 0.001).
Discussion
A corticosteroid switch from P 10 mg to D 0.5 mg was able to reverse biochemical resistance to AA+P in almost half of patients with mCRPC, and 38% of patients had major biochemical responses with a PSA decrease >50%. The median PFS on AA+D was 10.35 months, and was even longer than median time to PSA progression on AA+P (8.94 months). The median PFS on AA (AA+P and AA+D) was 20.07 months.
Limitations of our study are the retrospective analysis of this prospective cohort, single-centre recruitment, and the small sample size, which did not allow us to perform separate analyses according to previous chemotherapy administration, or to take into account known prognostic factors such as anaemia, lactic acid dehydrogenase and/or alkaline phosphatases in multivariate analysis. Moreover, results are We chose to use a single dose of 0.5 mg of D, according to the study by Lorente et al. [11] . This is less than the corticosteroid dose equivalence of 10 mg of P, but efficient enough to avoid the secondary mineralocorticoid excess caused by AA. This small dose of D may avoid some side effects such as hypertension or hypokalaemia, and is still able to induce a response. Nevertheless, further explorations may be required to highlight a possible dose effect.
The steroid switch efficacy at biochemical progression could be explained by a different action of D from that of P on the mechanism of resistance to AA, and/or by an intrinsic activity of D on tumour growth, and/or an interaction between D and AA pharmacokinetics.
Although novel ADT as AA and enzalutamide have demonstrated significant survival benefits in mCRPC, a significant proportion of patients have primary resistance to these agents and nearly all patients will develop secondary resistance. Mechanisms of resistance to these agents are not fully understood, but many AR-dependent and ARindependent hypotheses are emerging [14] . AR-dependent resistance mechanisms include upregulation of AR and cytochrome P450 17a-hydroxylase/17,20-lyase, induction of AR splice variants and AR point mutations. AR-independent resistance mechanisms include upregulation of glucocorticoid receptor (GR), activation of alternative oncogenic signalling pathways, neuroendocrine transformation, and immunemediated resistance mechanisms [15] .
The role of glucocorticoids and GR in prostate cancer is complex, because glucocorticoids can be both beneficial and harmful; however, GR upregulation and activation can be a clinically relevant mechanism of resistance to therapeutics targeting the AR signalling axis. Preclinical studies showed that increased GR expression was associated with enzalutamide and apalutamide resistance and that GR knockout could restore sensitivity to enzalutamide [16] . The mechanism of resistance to AA+P seems to be complex and is not yet fully understood. Exogenous glucocorticoid or mineralocorticoid antagonists administered to control AA side effects may differently impact mutant AR [17] , and/or GR overexpression.
The activity of D itself on prostate tumour growth may be involved, as indicated by phase I/II of D monotherapy used before the discovery of AA and enzalutamide in patients with mCRPC, in which D appears to be more active than prednisolone [18] . Corticosteroids decrease androgens and corticosteroid adrenal production, and lead to favourable biochemical and clinical responses. The efficacy of corticosteroids and other hormonal manipulations, which do not have a proven overall survival benefit, has not been established in randomized trials. D has also been shown to suppress tumour lymphangiogenesis in prostate cancer [19] .
To date, no data are available concerning AA pharmacokinetics when combined with D; this analysis is currently ongoing in another series of patients.
Three favourable prognostic factors were found in multivariate analysis: long androgen sensitivity duration; low PSA level at the time of switch; and short time to PSA progression on AA+P. The corticoid switch efficacy in patients progressing quickly with AA+P was unexpected. We observed that a short time to PSA progression with AA+P might be a prognostic factor of good and lasting responses to AA+D. We have no explanation or hypothesis for this surprising observation. While this may be a true effect, we cannot exclude the possibility that it could be statistically related to chance. Nevertheless, we decided to combine PSA level at the time of switch with hormone dependence duration rather than with the time to PSA progression on AA+P to build our prognostic score model because of the higher level of statistical significance in the multivariate Cox analysis. The limitations of this retrospective cohort study mean that this score requires further study in prospective evaluation for its clinical value to be confirmed.
The present study raises several questions about the coadministration of corticosteroids and AA. If co-administration of a corticosteroid with AA is requested as a result of AAinduced mineralocorticoid excess, we do not know if D could be better than P in first intent, or if it should be kept as a second-line therapy after AA+P at the time of biochemical resistance.
In conclusion, a corticosteroid switch from P to D may be able to reverse biochemical resistance to AA+P in almost half of patients with mCRPC. A longer PFS on AA+D has been observed in patients with previous long hormone sensitivity duration, and/or low PSA level at the time of switch and/or short time to PSA progression on AA+P. This steroid switch Logrank P < 0.001 is a non-expensive, safe and efficient way of obtaining longterm responses to AA in some patients.
A randomized study to determine clinical and radiological disease control with AA+P, followed by AA+D compared with AA+P alone in an asymptomatic patient with biochemical progression with AA+P is ongoing in order to prospectively validate the potential clinical value of this switch.
